Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 6 |
| List of Tables | 6 | 2 |
| List of Figures | 8 | 2 |
| Drug Discovery and Preclinical Molecules by Therapy Area Introduction | 10 | 2 |
| GBI Research Report Guidance | 11 | 1 |
| Drug Discovery and Preclinical Molecules by Therapy Area - Overview | 12 | 6 |
| Drug Discovery and Development | 12 | 1 |
| Drug Development-Stages | 13 | 1 |
| Early Stage Drug Discovery | 13 | 1 |
| Phase I | 14 | 1 |
| Phase II | 14 | 1 |
| Phase III | 14 | 1 |
| Registration | 14 | 1 |
| Phase IV | 15 | 1 |
| Early Stage Drug Discovery Studies- An overview | 15 | 1 |
| Early Stage Drug Discovery Design and Planning | 16 | 1 |
| Early Stage Drug Discovery Strategic Planning | 16 | 1 |
| Key Considerations During Early Stage Drug Discovery | 16 | 2 |
| Drug Discovery and Preclinical Molecules by Therapy Area - Technology Landscape | 18 | 9 |
| Current System | 18 | 1 |
| Overview | 18 | 1 |
| Key Technologies | 18 | 1 |
| In-vitro ADMET Screening Models | 19 | 1 |
| In vivo ADMET Screening Models | 20 | 1 |
| In silico ADMET Screening models | 21 | 1 |
| Trends in Technology Models | 22 | 1 |
| Recent Technology Developments | 22 | 5 |
| Drug Discovery and Preclinical Molecules by Therapy Area - Drug Discovery and Development A Challenge to Pharmaceutical Companies | 27 | 1 |
| Drug Discovery &Development Process | 27 | 1 |
| Drug Discovery Process | 27 | 1 |
| Drug Discovery and Preclinical Molecules in Therapeutic Segments | 28 | 158 |
| Central Nervous System Disorders | 31 | 1 |
| Alzheimer s disease | 31 | 1 |
| Drivers and Barriers for the Alzheimer s disease Therapeutics Market | 31 | 1 |
| Early Stage Research and Development Pipeline Alzheimer s disease | 32 | 3 |
| R&D Pipeline by Phase in Alzheimer s disease | 35 | 1 |
| R&D Pipeline by Mechanism of Action in Alzheimer s disease | 36 | 1 |
| Parkinson s disease | 37 | 1 |
| Drivers and Barriers for the Parkinson s disease Therapeutics | 37 | 1 |
| Early Stage Research and Development Pipeline Parkinson s disease | 38 | 2 |
| R&D Pipeline by Phase in Parkinson s disease | 40 | 1 |
| R&D Pipeline by Mechanism of Action in Parkinson s disease | 41 | 1 |
| Multiple Sclerosis | 42 | 1 |
| Drivers and Barriers for the Multiple Sclerosis Therapeutics Market | 42 | 2 |
| Early Stage Research and Development Pipeline Multiple Sclerosis | 44 | 1 |
| R&D Pipeline by Phase in Multiple Sclerosis | 45 | 1 |
| R&D Pipeline by Mechanism of Action in Multiple Sclerosis | 46 | 1 |
| Schizophrenia | 47 | 1 |
| Drivers and Barriers for the Schizophrenia Therapeutics Market | 48 | 1 |
| Early Stage Research and Development Pipeline Schizophrenia | 49 | 1 |
| R&D Pipeline by Phase in Schizophrenia | 50 | 1 |
| R&D Pipeline by Mechanism of Action in Schizophrenia | 51 | 1 |
| Metabolic Disorders | 52 | 1 |
| Diabetes | 52 | 1 |
| Drivers and Barriers for the Diabetes Therapeutics Market | 52 | 2 |
| Early Stage Research and Development Pipeline Diabetes | 54 | 3 |
| R&D Pipeline by Phase in Diabetes | 57 | 1 |
| R&D Pipeline by Mechanism of Action in Diabetes | 58 | 1 |
| Obesity | 59 | 1 |
| Drivers and Barriers for the Obesity Therapeutics Market | 59 | 2 |
| Early Stage Research and Development Pipeline Obesity | 61 | 2 |
| R&D Pipeline by Phase in Obesity | 63 | 1 |
| R&D Pipeline by Mechanism of Action in ObesityTherapeutics | 64 | 1 |
| Immunological Disorders | 65 | 1 |
| Rheumatoid Arthritis | 65 | 1 |
| Drivers and Barriers for the RA Therapeutics Market | 65 | 2 |
| Early Stage Research and Development Pipeline Rheumatoid ArthritisTherapeutics | 67 | 3 |
| R&D Pipeline by Phase in RA Therapeutics | 70 | 1 |
| R&D Pipeline by Mechanism of Action in Rheumatoid ArthritisTherapeutics | 71 | 1 |
| Crohn s Disease | 72 | 1 |
| Drivers and Barriers for the Crohn s Disease Therapeutics Market | 72 | 2 |
| Early Stage Research and Development Pipeline Crohn s Disease | 74 | 1 |
| R&D Pipeline by Phase in Crohn s Disease | 75 | 1 |
| R&D Pipeline by Mechanism of Action in Crohn s disease | 76 | 1 |
| Systemic Lupus Erythematosus (SLE) | 77 | 1 |
| Drivers and Barriers for the SLE Therapeutics Market | 77 | 2 |
| Early Stage Research and Development Pipeline Systemic Lupus Erythematosus Therapeutics | 79 | 1 |
| R&D Pipeline by Phase in Systemic Lupus Erythematosus Therapeutics | 80 | 1 |
| R&D Pipeline by Mechanism of Action in Systemic Lupus Erythematosus Therapeutics | 81 | 1 |
| Allergy | 82 | 1 |
| Drivers and Barriers for the Allergy Therapeutics Market | 82 | 2 |
| Early Stage Research and Development Pipeline Allergy Therapeutics | 84 | 1 |
| R&D Pipeline by Phase in Allergy Therapeutics | 85 | 1 |
| R&D Pipeline by Mechanism of Action in Allergy Therapeutics | 86 | 1 |
| Infections | 87 | 1 |
| HIV/AIDS | 87 | 1 |
| Drivers and Barriers for the HIV/AIDS Therapeutics Market | 87 | 5 |
| Early Stage Research and Development Pipeline HIV/AIDS Therapeutics | 92 | 2 |
| R&D Pipeline by Phase in HIV/AIDS Therapeutics | 94 | 1 |
| R&D Pipeline by Mechanism of Action in HIV/AIDS Therapeutics | 95 | 1 |
| Hepatitis A, B, C | 96 | 1 |
| Drivers and Barriers for the Hepatitis Therapeutics Market | 97 | 2 |
| Early Stage Research and Development Pipeline- Hepatitis A, B &C Therapeutics | 99 | 3 |
| R&D Pipeline by Phase in Hepatitis A, B &C Therapeutics | 102 | 1 |
| R&D Pipeline by Mechanism of Action in Hepatitis A, B &C Therapeutics | 103 | 1 |
| Cardiovascular Diseases | 104 | 1 |
| Hypertension | 104 | 1 |
| Drivers and Barriers for the Hypertension Therapeutics Market | 105 | 1 |
| Early Stage Research and Development Pipeline Hypertension Therapeutics | 106 | 1 |
| R&D Pipeline by Phase in Hypertension Therapeutics | 107 | 1 |
| R&D Pipeline by Mechanism of Action in HypertensionTherapeutics | 108 | 1 |
| Dyslipidemia | 109 | 1 |
| Drivers and Barriers for the Dyslipidemia Therapeutics Market | 109 | 2 |
| Early Stage Research and Development Pipeline Dyslipidemia Therapeutics | 111 | 1 |
| R&D Pipeline by Phase in Dyslipidemia Therapeutics | 112 | 1 |
| R&D Pipeline by Mechanism of Action in Dyslipidemia Therapeutics | 113 | 1 |
| Pulmonary Arterial Hypertension (PAH) | 114 | 2 |
| Drivers and Barriers for the PAH Therapeutics Market | 116 | 1 |
| Early Stage Research and Development Pipeline- PAH Therapeutics | 117 | 1 |
| R&D Pipeline by Phase in PAH Therapeutics | 117 | 1 |
| R&D Pipeline by Mechanism of Action in PAH Therapeutics | 118 | 1 |
| Myocardial Infarction | 119 | 1 |
| Drivers and Barriers for the Myocardial infarction Therapeutics Market | 120 | 1 |
| Early Stage Research and Development Pipeline Myocardial Infarction Therapeutics | 121 | 1 |
| R&D Pipeline by Phase in Myocardial Infarction Therapeutics | 122 | 1 |
| R&D Pipeline by Mechanism of Action in Myocardial Infarction Therapeutics | 123 | 1 |
| Oncology | 124 | 1 |
| Bladder Cancer | 124 | 1 |
| Drivers and Barriers for the Bladder Cancer Therapeutics Market | 125 | 1 |
| Early Stage Research and Development Pipeline Bladder Cancer Therapeutics | 126 | 1 |
| R&D Pipeline by Phase in Bladder Cancer Therapeutics | 127 | 1 |
| R&D Pipeline by Mechanism of Action in Bladder Cancer Therapeutics | 127 | 2 |
| Lung Cancer | 129 | 2 |
| Drivers and Barriers for the Lung Cancer Therapeutics Market | 131 | 2 |
| Early Stage Research and Development Pipeline Lung Cancer Therapeutics | 133 | 2 |
| R&D Pipeline by Phase in Lung Cancer Therapeutics | 135 | 1 |
| R&D Pipeline by Mechanism of Action in Lung Cancer Therapeutics | 136 | 1 |
| Non-Small Cell Lung Cancer (NSLC) | 137 | 2 |
| Drivers and Barriers for the NSLC Therapeutics Market | 139 | 1 |
| Early Stage Research and Development Pipeline NSLC Therapeutics | 140 | 1 |
| R&D Pipeline by Phase in NSLC Therapeutics | 141 | 1 |
| R&D Pipeline by Mechanism of Action in NSLC Therapeutics | 142 | 1 |
| Breast Cancer | 143 | 4 |
| Drivers and Barriers for the Breast Cancer Therapeutics Market | 147 | 1 |
| Early Stage Research and Development Pipeline Breast Cancer | 148 | 4 |
| R&D Pipeline by Phase in Breast Cancer Therapeutics | 152 | 1 |
| R&D Pipeline by Mechanism of Action in Breast Cancer Therapeutics | 153 | 1 |
| Colon Cancer | 154 | 3 |
| Drivers and Barriers for the Colon Cancer Therapeutics Market | 157 | 1 |
| Early Stage Research and Development Pipeline Colon Cancer Therapeutics | 158 | 3 |
| R&D Pipeline by Phase in Colon Cancer Therapeutics | 161 | 1 |
| R&D Pipeline by Mechanism of Action in Colon Cancer Therapeutics | 162 | 1 |
| Melanoma | 163 | 2 |
| Drivers and Barriers for the Melanoma Therapeutics Market | 165 | 1 |
| Early Stage Research and Development Pipeline Melanoma Therapeutics | 166 | 2 |
| R&D Pipeline by Phase in Melanoma Therapeutics | 168 | 1 |
| R&D Pipeline by Mechanism of Action in Melanoma Therapeutics | 169 | 1 |
| Ovarian Cancer | 170 | 1 |
| Drivers and Barriers for the Ovarian Cancer Therapeutics Market | 171 | 1 |
| Early Stage Research and Development Pipeline Ovarian Cancer Therapeutics | 172 | 2 |
| R&D Pipeline by Phase in Ovarian Cancer Therapeutics | 174 | 1 |
| R&D Pipeline by Mechanism of Action in Ovarian Cancer Therapeutics | 175 | 2 |
| Prostate Cancer | 177 | 1 |
| Drivers and Barriers for the Prostate Cancer Therapeutics Market | 178 | 1 |
| Early Stage Research and Development Pipeline Prostate Cancer Therapeutics | 179 | 4 |
| R&D Pipeline by Phase in Prostate Cancer Therapeutics | 183 | 1 |
| R&D Pipeline by Mechanism of Action in Prostate Cancer Therapeutics | 184 | 2 |
| Drug Discovery and Preclinical Molecules by Therapy Area Top Five Pharmaceutical Players in Early Stage Drug Discovery | 186 | 7 |
| Introduction | 186 | 1 |
| Hanall Pharmaceutical | 187 | 1 |
| Company Overview | 187 | 1 |
| Pipeline | 187 | 1 |
| Patrys Limited | 188 | 1 |
| Company Overview | 188 | 1 |
| Pipeline | 189 | 1 |
| F. Hoffmann-La Roche Ltd. | 189 | 1 |
| Company Overview | 189 | 1 |
| Pipeline | 190 | 1 |
| Mirna Therapeutics | 190 | 1 |
| Company Overview | 190 | 1 |
| Pipeline | 191 | 1 |
| Aphios Corporation | 191 | 1 |
| Company Overview | 191 | 1 |
| Pipeline | 192 | 1 |
| Drug Discovery and Preclinical Molecules by Therapy Area Strategic Consolidations | 193 | 9 |
| R&D Licensing Agreements | 193 | 1 |
| Deals by Indication | 193 | 1 |
| Deals by Geography | 194 | 1 |
| Deal Summaries by Therapeutic Class | 195 | 1 |
| Metabolic Disorders | 195 | 1 |
| Immunolgical Disorders | 196 | 2 |
| Cardiovascular Disorders | 198 | 1 |
| Infection | 199 | 1 |
| Oncology | 200 | 1 |
| Central Nervous System Disorders | 201 | 1 |
| Drug Discovery and Preclinical Molecules by Therapy Area Appendix | 202 | 8 |
| Market Definitions | 202 | 1 |
| Abbreviations | 202 | 5 |
| Research Methodology | 207 | 2 |
| Coverage | 207 | 1 |
| Secondary Research | 207 | 1 |
| Primary Research | 208 | 1 |
| Expert Panel Validation | 208 | 1 |
| Contact Us | 208 | 1 |
| Disclaimer | 208 | 1 |
| Sources | 209 | 1 |